CNTN1 and COVID-19: We aim to establish and validate a next-generation automated ELISA for anti-(para)nodal antibodies and investigate whether low-titer antibodies occur in recently COVID-19-vaccinated healthy individuals.<h4>Methods</h4>We used the Ella platform to customize an automated ELISA for anti-contactin-1, -neurofascin-155, and -Caspr-1 serum IgG.